630 related articles for article (PubMed ID: 16102838)
1. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
Lugnier C
Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
[TBL] [Abstract][Full Text] [Related]
2. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer with phosphodiesterase inhibitors.
Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
[TBL] [Abstract][Full Text] [Related]
4. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.
Keravis T; Thaseldar-Roumié R; Lugnier C
Methods Mol Biol; 2005; 307():63-74. PubMed ID: 15988055
[TBL] [Abstract][Full Text] [Related]
5. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
Gupta R; Kumar G; Kumar RS
Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
[TBL] [Abstract][Full Text] [Related]
6. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterases in the central nervous system.
Kleppisch T
Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
[TBL] [Abstract][Full Text] [Related]
9. Mammalian sperm phosphodiesterases and their involvement in receptor-mediated cell signaling important for capacitation.
Baxendale RW; Fraser LR
Mol Reprod Dev; 2005 Aug; 71(4):495-508. PubMed ID: 15856425
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterases regulate airway smooth muscle function in health and disease.
Krymskaya VP; Panettieri RA
Curr Top Dev Biol; 2007; 79():61-74. PubMed ID: 17498547
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value?
Albrecht K; Uckert S; Oelke M; Andersson KE; Jonas U; Tröger HD; Hedlund P
J Forensic Leg Med; 2007 Jul; 14(5):270-4. PubMed ID: 17113813
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
13. Cyclic nucleotide phosphodiesterases.
Essayan DM
J Allergy Clin Immunol; 2001 Nov; 108(5):671-80. PubMed ID: 11692087
[TBL] [Abstract][Full Text] [Related]
14. Cyclic nucleotide specific phosphodiesterases of Leishmania major.
Johner A; Kunz S; Linder M; Shakur Y; Seebeck T
BMC Microbiol; 2006 Mar; 6():25. PubMed ID: 16522215
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.
Gibson LC; Hastings SF; McPhee I; Clayton RA; Darroch CE; Mackenzie A; Mackenzie FL; Nagasawa M; Stevens PA; Mackenzie SJ
Eur J Pharmacol; 2006 May; 538(1-3):39-42. PubMed ID: 16674936
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular implications in the use of PDE5 inhibitor therapy.
Maurice DH
Int J Impot Res; 2004 Jun; 16 Suppl 1():S20-3. PubMed ID: 15224131
[TBL] [Abstract][Full Text] [Related]
17. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
Castro A; Jerez MJ; Gil C; Martinez A
Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors.
Zhang X; Feng Q; Cote RH
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3060-6. PubMed ID: 16123402
[TBL] [Abstract][Full Text] [Related]
19. Real-time monitoring of phosphodiesterase inhibition in intact cells.
Herget S; Lohse MJ; Nikolaev VO
Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.
Keravis T; Lugnier C
Br J Pharmacol; 2012 Mar; 165(5):1288-305. PubMed ID: 22014080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
